Retatrutide Phase 2 vs Phase 3: How Results Changed

The retatrutide Phase 2 results — 24.2% average body weight loss at the highest dose in 48 weeks (Jastreboff et al., NEJM 2023) — set an extraordinary benchmark. Now, with Phase 3 TRIUMPH trials underway, the central question is: will these results hold up? Understanding how Phase 2 and Phase 3 trials differ, and what historical precedent shows for similar drugs, helps set realistic expectations for the data that will determine retatrutide's path to FDA approval.

Key Differences Between Phase 2 and Phase 3

Factors That Could Improve Phase 3 Results

• Longer treatment duration: The Phase 2 weight loss curve was still descending at 48 weeks. With 72+ weeks of treatment, total weight loss could be meaningfully higher — potentially 26-30%.
• Optimized dose escalation: Phase 3 protocols incorporate Phase 2 tolerability data, using slower escalation to reduce side effects and improve adherence. Better adherence means more consistent drug exposure and potentially better results.
• Reduced dropout rates: Better tolerability through improved escalation should reduce discontinuation rates, and intention-to-treat analysis is sensitive to dropout rates.

Factors That Could Lower Phase 3 Results

• More diverse population: Phase 3 enrolls a broader, more representative population. Patients with more comorbidities or different demographics may respond somewhat differently than the Phase 2 population.
• Regression to the mean: Extremely positive Phase 2 results sometimes moderate slightly in larger samples. This is a statistical phenomenon, not a drug failure.
• Real-world conditions: Phase 3 trials, while still controlled, are conducted at more sites with varying levels of patient support. This can introduce more variability.
• Conservative dose selection: If Phase 3 uses a lower maximum dose than 12 mg for safety reasons, the average weight loss could be somewhat lower.

What Precedent Shows

The best predictor of Phase 2-to-Phase 3 consistency is how similar drugs performed:

Both semaglutide and tirzepatide showed Phase 3 results that closely matched or slightly exceeded Phase 2. The longer Phase 3 duration tended to increase total weight loss. This precedent is encouraging: retatrutide's Phase 3 results are likely to be in the same range or better than Phase 2.

Bottom Line Expectation

The most likely scenario for retatrutide Phase 3:

• Weight loss: 22-28% at the highest tested dose (slightly above or below Phase 2's 24.2%, depending on dose and duration)
• Responder rates: Similar to Phase 2, with 80%+ achieving 15%+ weight loss
• Side effects: Improved tolerability with optimized escalation; slightly lower dropout rates
• New data: Longer-term safety, specific comorbidity improvements, cardiovascular markers

Even at the lower end of expectations, retatrutide would remain substantially more effective than any currently available weight loss medication.

Proven Phase 3 Results Available Now

While retatrutide Phase 3 data is pending, medications with confirmed Phase 3 results are available:

• Compounded semaglutide: $99/month — Phase 3 confirmed 14.9% weight loss
• Compounded tirzepatide: $125/month — Phase 3 confirmed 22.5% weight loss

Learn more about how to get started.